Detailed dose evidence documented for Thymosin alpha-1 in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
In approved jurisdictions (e.g., Singapore label): Zadaxin 1.6 mg (900 mcg/m²) administered subcutaneously twice weekly for 6-12 months for chronic hepatitis B. For patients under 40 kg: 40 mcg/kg.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Chronic hepatitis C: 1.6 mg SC twice weekly for 6-12 months (in combination with interferon-based therapy).
COVID-19/sepsis: 1.6 mg SC daily or twice weekly in published observational studies.
Not established
What is not established
No FDA-approved dosing exists. This atlas did not verify a current, product-specific approved label for the other studied uses; authorization must be checked by product, indication, and jurisdiction.